Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
25.62
+0.56 (2.23%)
Sep 20, 2024, 4:00 PM EDT - Market closed
Nurix Therapeutics Income Statement
Financials in millions USD. Fiscal year is December - November.
Millions USD. Fiscal year is Dec - Nov.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | May '24 May 31, 2024 | Nov '23 Nov 30, 2023 | Nov '22 Nov 30, 2022 | Nov '21 Nov 30, 2021 | Nov '20 Nov 30, 2020 | Nov '19 Nov 30, 2019 | 2018 |
| Revenue | 62.3 | 76.99 | 38.63 | 29.75 | 17.82 | 31.12 | Upgrade
|
| Revenue Growth (YoY) | 2.25% | 99.31% | 29.84% | 66.95% | -42.73% | -16.91% | Upgrade
|
| Cost of Revenue | 196.5 | 189.15 | 184.5 | 116.43 | 66.49 | 45.03 | Upgrade
|
| Gross Profit | -134.19 | -112.16 | -145.87 | -86.68 | -48.67 | -13.91 | Upgrade
|
| Selling, General & Admin | 44.91 | 42.9 | 38 | 31.2 | 16.31 | 8.33 | Upgrade
|
| Operating Expenses | 44.91 | 42.9 | 38 | 31.2 | 16.31 | 8.33 | Upgrade
|
| Operating Income | -179.11 | -155.06 | -183.87 | -117.89 | -64.98 | -22.24 | Upgrade
|
| Interest & Investment Income | 14.28 | 11.12 | 3.51 | 0.82 | 1.21 | 0.78 | Upgrade
|
| Pretax Income | -164.82 | -143.95 | -180.36 | -117.06 | -63.78 | -21.46 | Upgrade
|
| Income Tax Expense | 0.18 | - | - | 0.13 | -20.54 | 0.24 | Upgrade
|
| Net Income | -165 | -143.95 | -180.36 | -117.19 | -43.24 | -21.7 | Upgrade
|
| Net Income to Common | -165 | -143.95 | -180.36 | -117.19 | -43.24 | -21.7 | Upgrade
|
| Shares Outstanding (Basic) | 57 | 54 | 49 | 43 | 16 | 3 | Upgrade
|
| Shares Outstanding (Diluted) | 57 | 54 | 49 | 43 | 16 | 3 | Upgrade
|
| Shares Change (YoY) | 6.22% | 11.79% | 13.32% | 173.68% | 376.03% | 16.87% | Upgrade
|
| EPS (Basic) | -2.92 | -2.65 | -3.71 | -2.73 | -2.76 | -6.59 | Upgrade
|
| EPS (Diluted) | -2.92 | -2.65 | -3.71 | -2.73 | -2.76 | -6.59 | Upgrade
|
| Free Cash Flow | -105.97 | -89.77 | -172.05 | -90.03 | -4.63 | -1.05 | Upgrade
|
| Free Cash Flow Per Share | -1.87 | -1.65 | -3.54 | -2.10 | -0.30 | -0.32 | Upgrade
|
| Gross Margin | -215.39% | -145.69% | - | -291.37% | -273.14% | -44.71% | Upgrade
|
| Operating Margin | -287.47% | -201.41% | -476.01% | -396.26% | -364.66% | -71.46% | Upgrade
|
| Profit Margin | -264.84% | -186.98% | -466.93% | -393.93% | -242.66% | -69.74% | Upgrade
|
| Free Cash Flow Margin | -170.08% | -116.60% | -445.42% | -302.61% | -26.00% | -3.37% | Upgrade
|
| EBITDA | -172.25 | -148.93 | -179.72 | -115.9 | -62.8 | -19.88 | Upgrade
|
| EBITDA Margin | -276.46% | -193.45% | - | - | - | -63.90% | Upgrade
|
| D&A For EBITDA | 6.86 | 6.13 | 4.15 | 1.99 | 2.18 | 2.35 | Upgrade
|
| EBIT | -179.11 | -155.06 | -183.87 | -117.89 | -64.98 | -22.24 | Upgrade
|
| EBIT Margin | -287.47% | -201.41% | - | - | - | -71.46% | Upgrade
|
| Revenue as Reported | 62.3 | 76.99 | 38.63 | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.